In-office urinary markers for bladder Ca: What's new

The key advantage of the new markers is their ability to identify patients with low-grade 'nuisance' tumors.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria